Previous close | 6.75 |
Open | 6.75 |
Bid | 5.60 |
Ask | 6.70 |
Strike | 47.00 |
Expiry date | 2024-06-28 |
Day's range | 6.75 - 6.75 |
Contract range | N/A |
Volume | |
Open interest | 1 |
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.